WCAF 2018 Program

For further details on each session below, just click on the title

Click here for a printer-friendly version of the program

This Group Learning program has been certified by the College of Family Physicians of Canada
and the British Columbia Chapter for up to 6.75 Mainpro+ credits

 

Thursday, May 3, 2018

Stop by the WCAF registration desk to register or check in for the event!

// Location: Ballroom Foyer //
Join us for light snacks and refreshments and a great opportunity to mingle with WCAF 2018 attendees as we welcome you to this year's event!

// Location: Cascade / Cassiar Room //

 

Friday, May 4, 2018

Time available for exhibitors to set up booths

// Location: Ballroom South //
Stop by the WCAF registration desk to register or check in for the event!

// Location: Ballroom Foyer //
// Location: Ballroom Foyer //
Open to all

// Location: Summit Room //
Opening remarks - Dr. Mandy Manak, Chair, WCAF Committee
Welcome - Gail Given, Deputy Mayor, City of Kelowna
Welcome - Doug Hughes, Deputy Minister, Ministry of Health and Addictions, Government of British Columbia
EventMobi (Conference App) Introduction - Brett Baumback, WCAF Committee

// Location: Okanagan Room //
The Sinclair Method is a highly effective treatment for alcohol use disorder. Over the last two decades, three quarters of patients treated at clinics in Finland have achieved long-term recovery using the treatment. The Sinclair Method lowers treatment barriers, reduces alcohol consumption, and increases the likelihood of recovery success. Yet in spite of the benefits, many physicians have not heard of this treatment method pioneered almost thirty years ago. Others, due to the off-label nature of naltrexone, hesitate to embrace the treatment and its benefits. Discuss barriers that have kept it from becoming more popular, and equip medical professionals with information they can use to immediately incorporate The Sinclair Method into their practice.

// Location: Okanagan Room //
This presentation will examine the increasing numbers of clients who find themselves entrapped in a sexually compulsive cycle. The presentation will review current trends in sex and porn addiction. Focus will also be given on how to assess the issues and refer to treatment.

// Location: Okanagan Room //
With the impending legalization of cannabis, employers need to be aware of the inevitable increase in the number of workers consuming cannabis on a regular basis - recreationally and for medical purposes - and the impact it will have on workplace safety and productivity.

// Location: Okanagan Room //
This session will highlight common clinical issues seen in CMPA cases that relate to opioid prescribing in Canada. Medical-legal risks associated with opioid prescribing will be reviewed, as well as recommended provincial and national standards for safe prescribing to enhance best practices in patient care.

// Location: Okanagan Room //
With legalization of cannabis in Canada, evidence-based knowledge translation activities are important for public awareness and education. The role of cannabis in psychosis development and outcomes will be discussed and approach to youth targeted information using this information will be illustrated.

// Location: Okanagan Room //
// Location: Ballroom South //
This year the BCCDC received a federal grant for a pilot project to distribute tablets of hydromorphone for take-home unsupervised injection in an attempt to mitigate the high opioid overdose rates in Vancouver and Victoria. This session will begin with an outline of the rationale and logistics behind this project along with its hoped for outcome. Next, possible consequences of this approach will be explored including unintended harms. Finally, alternative approaches to the proposed strategy will be presented. Then group discussion will be encouraged, including the questions "What do you think of the proposed take-home hydromorphone for self-injection project?" and "Are there other approaches you would like to see implemented in addiction instead?"

// Location: Okanagan Room //
This presentation will outline the stigma of substance use disorder in the form of stereotypes (ie. beliefs), prejudices (ie. emotional reactions) and discrimination (ie. behaviours). This will in turn lead to a discussion about strategies to change and eliminate the stigma of SUD.

// Location: Okanagan Room //
Develop an understanding of the importance of HCV infection among people who use drugs, the importance of a multidisciplinary approach to engaging people who use drugs in long-term health care, and the role established medical structures can play in reducing overdose-related deaths.

// Location: Okanagan Room //
Identify the costs and benefits of disclosing one's experience with SUD in order to deal with the public and self-stigma of SUD. Learn the basics of Honest, Open Proud as a vehicle to accomplish self-disclosure goals. Discuss adaptation of HOP for people with SUD.

// Location: Okanagan Room //
// Location: Ballroom South //
Learn more about: safe prescribing of opioids; tapering, substitution, and exit strategies; various pharmacological and non-pharmacological strategies for the treatment of chronic non-cancer pain; community and regional resources, including WorkSafeBC programs; and more.

Click here for more information

This event is fully funded by WorkSafeBC and dinner will be provided

// Location: Mount Boucherie Room //

 

Saturday, May 5, 2018

Stop by the WCAF registration desk to register or check in for the event!

// Location: Ballroom Foyer //
// Location: Ballroom Foyer //
Open to all

// Location: Summit Room //
The Sinclair Method is a treatment for alcohol use disorder that uses naltrexone to produce a reduction in heavy drinking. The treatment is not new, nor is it experimental, but due to its off-label use of naltrexone in conjunction with alcohol, medical professionals may hesitate to embrace it. This presentation covers the most relevant information needed to begin treating patients with alcohol use disorder using The Sinclair Method. Topics include an overview of the treatment protocol, contraindications, best practices, and tips for overcoming common obstacles to recovery success.

// Location: Okanagan Room //
Identification and management tools for non-medical risks encountered in addiction healthcare.

// Location: Okanagan Room //
An overview of an iOAT program that has operated in a community pharmacy for a year. The challenges and successes of the program along with areas of improvement will be presented. In this presentation we will also review the evidence for iOAT and an overview of caring for a patient on iOAT.

// Location: Okanagan Room //
Our patients with addiction currently face a maze of obstacles and gaps in the continuum of care. This results in unnecessary relapse and worse, for some. We will describe essential components of a community based recovery oriented system of care and valuable recovery management services primary healthcare providers are ideally positioned to provide.

// Location: Okanagan Room //
// Location: Ballroom South //
A review of the Calgary Zone Guidelines for patients during hospital admission for acute pain and peri-surgical treatments on buprenorphine/naloxone treatment

// Location: Okanagan Room //
Buprenorphine/naloxone is recognized as first-line therapy for opioid use disorder, but the requirement for moderate withdrawal prior to initiation to avoid precipitated withdrawal can be a barrier to its initiation. We present two induction strategies which eliminate the need for withdrawal during the induction phase including transdermal fentanyl bridge as well as buprenorphine microdosing.

// Location: Okanagan Room //
The presentation will be about my journey with opioid use disorder and addiction, with a particular emphasis on methadone and how I successfully tapered off.

// Location: Okanagan Room //
This presentation will review the efficacy, safety of an implantable formulation of buprenorphine for the treatment of opioid use disorder. Discussion will include the insertion and removal procedures, dosing and patient selection.

// Location: Okanagan Room //
The effects of RBP-6000 on abstinence and craving in patients with opioid use disorder (OUD) were assessed in a 24-week, double-blind trial. RBP-6000 was significantly superior to placebo (P<0.001), with mean percentage abstinence rates of 41.3% (300/300 mg; n=196), 42.7% (300/100 mg; n=194), and 5.0% (placebo; n=99). Exposure-response analyses showed buprenorphine plasma concentrations ≥2ng/mL consistently delivered across the entire monthly dosing period led to increased abstinence, reduced withdrawal symptoms, and reduced opioid craving. Safety and tolerability were acceptable. The effect of monthly depot buprenorphine, RBP-6000, on patient-reported recovery-related outcomes, including health status, health-related quality of life (HRQoL), treatment satisfaction, and employment status, was assessed in a 24-week, Phase III, placebo-controlled study in 489 participants with opioid use disorder (OUD). Compared with placebo, RBP-6000 was associated with significant improvements in health status, HRQoL and treatment satisfaction from baseline to end of study. Additionally, RBP-6000 was associated with increased employment. // Location: Okanagan Room //

 

Sunday, May 6, 2018

People who inject drugs (PWID) represent approximately 90% of newly acquired hepatitis C (HCV) infections. Clinicians working with PWID play an important role in reducing HCV-related morbidity and mortality through early diagnosis and treatment.
With the advent of new, well-tolerated, short-course direct acting antiviral (DAA) HCV regimens with cure rates >95%, there is an opportunity to vastly improve the health outcomes of people living with HCV.
This course is designed for medical practitioners, nurses, addiction medicine specialists and other clinical staff working with people who inject drugs. Through online learning and a face-to-face workshop, delivered by local experts, participants will gain the skills to confidently manage hepatitis C in their setting.

Click here for more information

The course is free of charge; refreshments, morning and afternoon tea and lunch will be provided.

// Location: TBA //

* program is subject to change